Article | February 17, 2012
The FDA announced a warning to healthcare professionals and patients about a counterfeit version of Avastin 400mg/16mL, which may have been purchased and used by some medical practices in the United States.
The counterfeit version is labeled as Avastin, manufactured by Roche and does not contain the medicine's active ingredient, bevacizumab, which my have resulted in patients not receiving needed therapy.
Avastin is an injectable medicine used to treat various types of cancer, including brain cancer, and is administered to patients in clinics, hospitals, and doctors' offices.
Click here for FDA announcement.
Click here for Genentech/Roche announcement.
